Quick Answer
QIAGEN N.V. reported Cash and Equivalents of $839.00 million for fiscal year 2025.
QIAGEN N.V. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $839.00M | +26.4% |
| 2024 | $663.55M | -0.7% |
| 2023 | $668.08M | -8.6% |
| 2022 | $730.67M | -17.0% |
| 2021 | $880.52M | +47.2% |
| 2020 | $597.98M | -4.1% |
| 2019 | $623.65M | -46.2% |
| 2018 | $1.16B | +76.2% |
| 2017 | $657.71M | +49.8% |
| 2016 | $439.18M | +51.4% |
| 2015 | $290.01M | -26.1% |
| 2014 | $392.67M | +18.9% |
| 2013 | $330.30M | -16.2% |
| 2012 | $394.04M | +78.2% |
| 2011 | $221.13M | -73.3% |
| 2010 | $828.41M | +0.3% |
| 2009 | $825.56M | +147.7% |
| 2008 | $333.31M | -4.0% |
| 2007 | $347.32M | — |
- QIAGEN N.V. showed an increase of +26.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, QIAGEN N.V.’s cash and equivalents has grown by 141.6% (from $347.32 million to $839.00 million).
- The most recent figure is from QIAGEN N.V.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: